MedTrace Logo

Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study

NCT01371929 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2023-11-18

No results posted yet for this study

Summary

The primary objective is to demonstrate that the plasma inducible nitric oxide synthase (iNOS) assay (PliNOSa® test) has an acceptable relative risk ratio for predicting the onset of sepsis within 72 hours of testing when performed on the first day a patient is admitted or transferred to the intensive care unit (ICU) and is considered to be at risk of becoming septic. The PliNOSa® test measures inducible nitric oxide synthase (iNOS) in plasma and uses a pre-determined iNOS cut-off value to identify patients at risk for the onset of the sepsis pathology.

Conditions

  • Sepsis
  • Severe Sepsis
  • Septic Shock

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • Research & Diagnostic Antibodies

    lead INDUSTRY

Principal Investigators

  • Robert J Webber, Ph.D. · Research & Diagnostic Antibodies

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-04
Primary Completion
2015-09-30
Completion
2015-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01371929 on ClinicalTrials.gov